Revenue rose to KRW 4.87 trillion in FY2025, but operating profit fell due to global competition in key products. Major investments in aramid and PMR capacity, ongoing mergers, and a stable dividend policy position the company for gradual recovery and future growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.